Hepatoprotective effect of Omega-3 PUFAs against acute paracetamol-induced hepatic injury confirmed by FTIR.
Acetaminophen
/ toxicity
Alanine Transaminase
/ blood
Analgesics, Non-Narcotic
/ toxicity
Animals
Aspartate Aminotransferases
/ blood
Chemical and Drug Induced Liver Injury
/ blood
Cholesterol
/ blood
Fatty Acids, Omega-3
/ pharmacology
Female
Glutathione
/ metabolism
Hepatocytes
/ drug effects
Interleukin-6
/ blood
Liver
/ drug effects
Malondialdehyde
/ metabolism
Nitric Oxide
/ metabolism
Protective Agents
/ pharmacology
Rats, Wistar
Spectroscopy, Fourier Transform Infrared
Tumor Necrosis Factor-alpha
/ metabolism
FTIR
Omega-3
liver injury
paracetamol
Journal
Human & experimental toxicology
ISSN: 1477-0903
Titre abrégé: Hum Exp Toxicol
Pays: England
ID NLM: 9004560
Informations de publication
Date de publication:
Mar 2021
Mar 2021
Historique:
pubmed:
11
9
2020
medline:
25
2
2023
entrez:
10
9
2020
Statut:
ppublish
Résumé
Acute paracetamol over dose-induced hepatotoxicity is considered an important medical hazard especially among women. Omega-3 long-chain polyunsaturated fatty acids (Omega-3 PUFAs) daily doses are nowadays recommended for their antioxidant and anti-inflammatory potentials. Fourier transform infrared (FTIR) spectroscopy is considered a reliable method in analyzing cellular alterations and is now efficiently used to diagnose several diseases and the efficacy of drugs even in the early stages. The aim of our study was to evaluate the hepatoprotective effect of Omega-3 PUFAs against paracetamol-induced hepatotoxicity in rats confirmed through measuring protein alterations in hepatocytes by FTIR. Rats were pretreated with Omega-3 PUFAs (50 and 100 mg/kg) for 21 days prior to oral ingestion of paracetamol. FTIR results revealed that Omega-3 PUFAs (50 mg/kg) limited the toxic effects of paracetamol by restoring the hepatic amide I to amide II ratio. In addition; biochemical analyses demonstrated that serum ALT, AST, Cholesterol, LDL-cholesterol and Il-6 levels as well as hepatic TNF-α, MDA, NOx levels were decreased. Besides; serum HDL-cholesterol level and hepatic GSH level were increased. Histopathological examinations of hepatic sections validated the hepatoprotective potential. The overall effect of this dose was comparable to those of the usual recommended hepatoprotective supplement; silymarin. In conclusion; it would be recommended to use Omega-3 PUFAs in low doses on daily bases as a hepatoprotective agent.
Identifiants
pubmed: 32909844
doi: 10.1177/0960327120954522
doi:
Substances chimiques
Analgesics, Non-Narcotic
0
Fatty Acids, Omega-3
0
Il6 protein, rat
0
Interleukin-6
0
Protective Agents
0
Tumor Necrosis Factor-alpha
0
Nitric Oxide
31C4KY9ESH
Acetaminophen
362O9ITL9D
Malondialdehyde
4Y8F71G49Q
Cholesterol
97C5T2UQ7J
Aspartate Aminotransferases
EC 2.6.1.1
Alanine Transaminase
EC 2.6.1.2
Glutathione
GAN16C9B8O
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM